AbbVie revealed it has raised its annual profit forecast for 2025 after sales of its newest immunology drugs Skyrizi and Rinvoq strengthened the company’s Q3 sales number, exceeding expectations set by Wallstreet.¹

“AbbVie continues to deliver outstanding results, with significant momentum across key areas of our portfolio. We are also making great progress advancing our pipeline and investing in innovation to support AbbVie's long-term growth," said Robert A. Michael, chairman and chief executive officer at AbbVie. "Based upon the strength of our business and its promising outlook, we are once again raising our quarterly cash dividend."

What is AbbVie raising its 2025 profit forecast to?

AbbVie is expected to raise its 2025 annual profit-per-share amount from between $10.38 and $10.58 to $10.61 and $10.65.¹ The raise comes as a reaction to the company’s quarterly sales, which reached $15.78 billion worldwide for the third quarter, a 9.1% increase on reported basis, and a 8.4% increase on an operational basis.² During the entire quarter, AbbVie noted that Skyrizi brought in sales upwards of $4.71 billion, which surpassed the previous estimates of $4.44 billion. Rinvoq sales also reached $2.18 billion, topping its estimates of $2.12 billion.¹

What was AbbVie’s third quarter sales results?

According to AbbVie’s news release, the company earned quarterly profit-per-share of $1.86, which outperformed its estimates of $1.77-per-share. However, AbbVie said its quarterly results also include an negative impact of $1.50-per-share related to its acquired in-process research and development expenses.²

AbbVie’s reported global net revenue from its immunology, neuroscience, oncology, and aesthetics portfolios were as follows:

• Immunology portfolio: $7.8 billion, an increase of 11.9% on a reported basis, or 11.2% on an operational basis.
• Neuroscience portfolio: $2.8 billion, an increase of 20.2% on a reported basis, or 19.6% on an operational basis.
• Oncology portfolio: $1.6 billion, a decrease of 0.3% on a reported basis, or 1.3% on an operational basis.
• Aesthetics portfolio: $1.1billion, a decrease of 3.7% on a reported basis, or 4.2% on an operational basis.

In its press release, AbbVie listed additional key third quarter net revenue metrics, including the following:

• Global Skyrizi: $4.708 billion, an increase of 46.8% on a reported basis, or 46.0% on an operational basis.
• Global Rinvoq: $2.184 billion, an increase of 35.3% on a reported basis, or 34.1% on an operational basis.
• Global Humira: $993 million, a decrease of 55.4% on a reported basis, or 55.7% on an operational basis.
• Global Vraylar: $934 million, an increase of 6.7%.
• Global Botox Therapeutic: $985 million, an increase of 16.1% on a reported basis, or 15.8% on an operational basis.

AbbVie’s investment into US-based manufacturing

As many other large pharma companies have this year, AbbVie announced plans to invest in US-based manufacturing facilities, including construction on its North Chicago-based manufacturing plant in August of this year. The $195 million manufacturing facility reflects the company’s commitment to expanding its US-based manufacturing presence, as the new facility will enable AbbVie to move some of its manufacturing capabilities from Europe and Asia to the United States.

AbbVie executive vice president and chief operations officer Azita Saleki-Gerhardt, PhD, touched on the investment into the facility, saying, “Today's groundbreaking is an important milestone in AbbVie's ongoing campaign to accelerate biopharmaceutical innovation and manufacturing capabilities in the U.S. Over the next decade, AbbVie plans to invest more than $10 billion in capital to add multiple new U.S. manufacturing plants and improve the lives of millions of patients in the U.S. and worldwide who depend on our medicines."

Sources

1. AbbVie lifts annual profit forecast on resilient demand for newer immunology drugs Reuters October 31, 2025 https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-lifts-annual-profit-forecast-resilient-demand-newer-immunology-drugs-2025-10-31/
2. AbbVie Reports Third-Quarter 2025 Financial Results AbbVie October 31, 2025 https://news.abbvie.com/2025-10-31-AbbVie-Reports-Third-Quarter-2025-Financial-Results